首页 > 市场调查报告书 > 製药

循环系统

市场调查报告书

商品编码

1629686

心源性休克治疗市场：依治疗类型、最终用户、地区

Cardiogenic Shock Treatment Market, By Treatment Type, By End User, By Geography

出版日期: 2024年11月27日 | 出版商:

Coherent Market Insights | 英文 161 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计2024年全球心源性休克治疗市场规模为11亿美元，预计2031年将达17.8亿美元，2024年至2031年复合年增长率为7.1%。

报告范围		报告详情
基准年	2023年	2024年市场规模	11亿美元
实际资料	2019-2023	预测期	2024-2031
预测 2024-2031 年复合年增长率：	7.10%	2031年价值预测	17.8亿美元

图：2024 年按地区分類的心源性休克治疗市场占有率(%)

心源性休克是一种危及生命的疾病，心臟突然停止泵送足够的血液来满足身体的需求。这种疾病可能是由心臟病发作、心血管手术后的併发症和心肌感染疾病等情况引起。如果不及时治疗，可能会迅速发生器官衰竭并导致死亡。全球心血管疾病的增加以及对复杂心臟疾病有效管理的需求不断增加是预计未来几年推动全球心源性休克治疗市场成长的主要因素。

市场动态：

全球心源性休克治疗市场主要是由冠状动脉疾病、心臟病和心臟衰竭等心血管疾病的盛行率不断上升所推动的。根据世界卫生组织 (WHO) 统计，2021 年 6 月，心血管疾病是全球第一大死因，估计每年夺走超过 1,790 万人的生命。此外，市场的成长也受到越来越多的老年人的支持，他们更有可能患上这种严重的心臟疾病。机械循环支援设备各种技术的进步以及这些有效管理方案的快速采用正在提供新的机会。然而，与设备和外科手术相关的高成本阻碍了低收入地区的市场渗透。此外，公众缺乏对早期诊断和管理方案的认识也是一个挑战。

本研究的主要特点

该报告对全球心源性休克治疗市场进行了详细分析，并提供了以2023年为基准年的预测期（2024-2031年）的市场规模和年复合成长率（CAGR%）。

它还揭示了各个细分市场的潜在商机，并说明了该市场有吸引力的投资提案矩阵。

它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的主要考察。

根据公司亮点、产品系列、主要亮点、绩效和策略等参数对全球心源性休克治疗市场的主要企业进行了分析。

本研究涵盖的主要企业包括 Abbott、Medtronic、Getinge AB、Abiomed、Terumo Corporation、Boston Scientific、F. Hoffmann-La Roche Ltd、Bayer AG、Viatris Inc.、Par Pharmaceutical、AstraZeneca、Zoll Medical Corporation，其中包括 Xenios AG （Fresenius Medical Care 的一部分）、Windtree Therapeutics 和Chiesi Farmaceutici SpA。

该报告的见解使负责人和公司经营团队能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。

全球心源性休克治疗市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。

透过用于分析全球心源性休克治疗市场的各种策略矩阵，将促进相关人员的决策。

Report Coverage	Report Details
Base Year:	2023	Market Size in 2024:	US$ 1.10 Bn
Historical Data for:	2019 To 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	7.10%	2031 Value Projection:	US$ 1.78 Bn

Cardiogenic shock is a life-threatening condition in which the heart suddenly fails to pump enough blood to meet the body's need. This failure can result from conditions like heart attack, complications after heart surgery, or heart muscle infection. Without prompt treatment it can rapidly lead to organ dysfunction and death. Globally rising cases of cardiovascular diseases and increasing demand for effective management of complex cardiac conditions are the major factors anticipated to boost the growth of the cardiogenic shock treatment market worldwide in the coming years.

Market Dynamics:

The global cardiogenic shock treatment market is primarily driven by the increasing prevalence of cardiovascular diseases such as coronary artery disease, heart attacks, and heart failures. According to the World Health Organization, in June 2021, cardiovascular diseases are the leading cause of deaths globally, taking an estimate of over 17.9 million lives each year. Moreover, rising geriatric population susceptible to develop such critical cardiac conditions also supports the market growth. Various technological advancements in mechanical circulatory support devices and rapid adoption of these effective management options offer new opportunities. However, high cost associated with devices and surgical procedures hampers market penetration in low-income regions. Additionally, lack of awareness among people about early diagnosis and management options pose challenges.

Key Features of the Study:

This report provides in-depth analysis of the global cardiogenic shock treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global cardiogenic shock treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Abbott, Medtronic, Getinge AB, Abiomed, Terumo Corporation, Boston Scientific, F. Hoffmann-La Roche Ltd, Bayer AG, Viatris Inc., Par Pharmaceutical, AstraZeneca, Zoll Medical Corporation, Xenios AG (part of Fresenius Medical Care), Windtree Therapeutics, and Chiesi Farmaceutici S.p.A.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global cardiogenic shock treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cardiogenic shock treatment market

Market Segmentation

Treatment Type Insights (Revenue, USD Bn, 2019 - 2031)
- Mechanical Support Devices
- Pharmacological Treatments:
- Surgical Procedures
- Others
End User Insights (Revenue, USD Bn, 2019 - 2031)
- Hospitals
- Cardiac Care Centers
- Ambulatory Surgical Centers
- Others
Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Abbott
- Medtronic
- Getinge AB
- Abiomed
- Terumo Corporation
- Boston Scientific
- F.Hoffmann-La Roche Ltd
- Bayer AG
- Viatris Inc.
- Par Pharmaceutical
- AstraZeneca
- Zoll Medical Corporation
- Xenios AG (part of Fresenius Medical Care)
- Windtree Therapeutics
- Chiesi Farmaceutici S.p.A.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Cardiogenic Shock Treatment Market, By Treatment Type
- Global Cardiogenic Shock Treatment Market, By End User
- Global Cardiogenic Shock Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Cardiogenic Shock Treatment Market, By Treatment Type, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Mechanical Support Devices
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Pharmacological Treatments:
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Surgical Procedures
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Global Cardiogenic Shock Treatment Market, By End User, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Cardiac Care Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Cardiogenic Shock Treatment Market, By Region, 2019 - 2031, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2024, 2027 & 2031, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Treatment Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

7. Competitive Landscape

Abbott
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Medtronic
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Getinge AB
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Abiomed
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Terumo Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Boston Scientific
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
F.Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Par Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Zoll Medical Corporation
Xenios AG (part of Fresenius Medical Care)
Windtree Therapeutics
Chiesi Farmaceutici S.p.A.

8. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

9. References and Research Methodology

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

心源性休克治疗市场：依治疗类型、最终用户、地区